Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.74 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437069 | 1.00 | CA2 (0.74) | CA2CA1LMNAHTR6ALDH1A1 | |
| SCHEMBL443016 | 0.85 | CA2 (1.00) | CA2CA1LMNAHTR6ALDH1A1 | |
| SCHEMBL407066 | 0.85 | CA2 (1.00) | CA2CA1LMNAHTR6ALDH1A1 | |
| SCHEMBL440704 | 0.85 | CA2 (1.00) | CA2CA1LMNAHTR6ALDH1A1 | |
| SCHEMBL440703 | 0.85 | CA2 (1.00) | CA2CA1LMNAHTR6ALDH1A1 | |
| SCHEMBL437933 | 0.83 | CA2 (1.00) | CA2CA1LMNAALDH1A1 | |
| SCHEMBL441036 | 0.83 | CA2 (1.00) | CA2CA1LMNAALDH1A1 | |
| SCHEMBL443132 | 0.81 | CA2 (0.67) | CA2CA1LMNAHTR6ALDH1A1 | |
| SCHEMBL443131 | 0.81 | CA2 (0.67) | CA2CA1LMNAHTR6ALDH1A1 | |
| SCHEMBL407199 | 0.81 | CA2 (1.00) | CA2CA1LMNAHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768970-B1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| EP-1768970-B1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-1968572-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2276481-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | STS, GABRB2, SULT2A1 | CA2 826/4885CA1 137/4885LMNA 2256/4885 |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | CA2 917/4885CA1 421/4885LMNA 4711/4885 |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | CA2 917/4885CA1 421/4885LMNA 4711/4885 |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | SDHA, SQOR, SDHB | CA2 3045/4885CA1 2365/4885LMNA 4373/4885 |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | GABBR1, GABBR2, SQOR | CA2 2789/4885CA1 1552/4885LMNA 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.